MEETINGS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Duration (min) |
Begin |
End |
Speaker |
Title |
|
8:30 |
8:45 |
Marilyn Martinez |
Introduction and objectives |
0:40 |
8:45 |
9:25 |
Terrance Ocheltree |
Quality by Design: impact on drug development and its global applications |
0:40 |
9:25 |
10:05 |
Raafat Fahmy |
Design space and product specifications: a risk assessment approach |
0:40 |
10:05 |
10:45 |
Arzu Selen |
Quality Product Target Profile: Integrating product in vivo performance in a patient population with product design. |
0:15 |
10:45 |
11:00 |
Break |
|
0:40 |
11:00 |
11:40 |
Kevin Johnson |
Development of oral drug delivery platforms based upon patient GI characteristics |
0:20 |
11:40 |
12:00 |
Audience Discussion |
|
1:00 |
12:00 |
13:00 |
Lunch |
|
0:40 |
11:00 |
11:40 |
Adrian Dunne |
A nonlinear mixed effects IVIVC model for multi-release drug delivery systems |
0:40 |
13:40 |
14:20 |
Roger Jelliffe |
The use of therapeutic drug monitoring to identify the relationships between optimized dosing strategies (input function) versus patient characteristics (covariates): Using this information to develop a target for in vivo product release characteristics |
0:40 |
14:20 |
15:00 |
William Jusko, |
The development of mechanistic population pharmacokinetic models to support the development of targeted release characteristics from modified release dosage forms |
0:20 |
15:00 |
15:20 |
Break |
|
0:40 |
15:20 |
16:00 |
Jeffrey Barrett |
The use of modeling and simulation to target dosing strategies and predict optimal in vivo product release characteristics in a pediatric population. |
0:40 |
16:00 |
16:40 |
Maria Cruanes, |
Integrating patient in vivo performance characteristics into product design and specifications: a manufacturing perspective. |
0:20 |
16:40 |
17:00 |
Round Table Discussion and Audience Participation |
|
0:10 |
16:00 |
16:10 |
Marilyn Martinez |
Closing comments and adjourn |